REQUEST A DEMO
Please fill your contact details below:
ACCELERATING DRUG DISCOVERY. TODAY.
Biomolex AS is a Norwegian biotech company that was established as a joint venture between The Norwegian Radium Hospital (NRH) and Ideas ASA (Ideas) in May 2001. Biomolex has developed a unique patented microarray reader - an imaging system for gene and protein analysis.
We provide tools that accelerate drug discovery, enable precision medicine and increase the quality of data in research. Our vision is to become a unique supplier of kinase arrays for diagnostics and drug development.
The Biomolex digital radiography system provides real time detection of multiple radioisotope labels. With a higher sensitivity than classical phosphorimagers, we aim to make molecular imaging more precise.
Chairman of the Board
Håvard Hildeng Hauge
Chief Executive Officer
Double Sided Silicon Strip
Superior Image Quality and Detail
PepChip® Kinase substrate arraySlide incubated with cell-lysate and P33 labelled ATP. © 2001-2016, Biomolex AS.
Line Profile, DSSD SystemTop: Digital autoradiography images of the same sample of segments of 18 μm thick wires, showing the Co-58 activity from the DSSD system for 93h (A), and a storage phosphor screen system for 144h, scanned at 600dpi (B). Background was subtracted and both images were individually scaled from zero (white) to max (black) intensity. Bottom: examples of intensity line profiles from one of the lines in the images above, measured using the DSSD system (C) and the phosphor screen (D). © 2013, A. Örbom
Aorta: Oil Red O vs. Biomolex 700From left to right, the animal aorta was stained with Oil Red O to identify the lipid deposits followed by the processed Oil Red O image to define plaque and non-plaque areas. Finally, with a 5x5-pixel mean filter applied, digital autoradiography images of the same aorta, separated into contributions from the different radiotracers. Each image is individually scaled from zero (white) to max (black) uptake and does not reflect differences in total uptake between tracers. © 2013, Anders Örbom.
03 / DISRUPTIVE
Our system aims to transform the drug discovery process, starting with kinase drug targets for oncology.
02 / HIGH RESOLUTION
Our radiographic labelling of molecules allows for a higher resolution than conventional molecular imaging.
01 / FAST
Biomolex has developed a unique technology that allows for faster image acquisition than conventional technology.